A Randomized Phase II Trial of First-Line Metastatic Breast Cancer (MBC) Patients: Sub-Set Analysis of Albumin-Bound Paclitaxel (ab-pac) Given Weekly at 150 mg/m2.

被引：0
|
作者：
Gradishar, W. J. [1 ]
Krasnojon, D. [1 ]
Cheporov, S. [1 ]
Makhson, A. N. [1 ]
Manikhas, G. M. [1 ]
Clawson, A. [1 ]
Bhar, P. [1 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-P5-19-13
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-19-13
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Albumin-Bound Paclitaxel (ab-pac) Versus Docetaxel for First-Line Treatment of Metastatic Breast Cancer (MBC): Overall Survival and Safety Analysis of a Randomized Phase II Trial.
    Gradishar, W. J.
    Krasnojon, D.
    Cheporov, S.
    Makhson, A. N.
    Manikhas, G. M.
    Clawson, A.
    Bhar, P.
    CANCER RESEARCH, 2011, 71
  • [2] Albumin-bound paclitaxel (ab-pac) versus docetaxel for first-line treatment of metastatic breast cancer (MBC): Final overall survival (OS) analysis of a randomized phase II trial.
    Gradishar, W. J.
    Krasnojon, D.
    Cheporov, S. V.
    Makhson, A.
    Manikhas, G. M.
    Clawson, A.
    Bhar, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
  • [3] Albumin-bound Paclitaxel (ab-pac) Versus Docetaxel for First-line Treatment of Metastatic Breast Cancer (MBC): Overall Survival (OS) Subset Analyses of a Randomized Phase 2 Trial
    Gradishar, W. J.
    Krasnojon, D. A.
    Cheporov, S. V.
    Makhson, A. N.
    Manikhas, G. M.
    Clawson, A.
    Bhar, P.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S348 - S348
  • [4] Phase II Multicenter Trial of Albumin-Bound Paclitaxel and Capecitabine in First-Line Treatment of Patients With Metastatic Breast Cancer
    Schwartzberg, Lee S.
    Arena, Francis P.
    Mintzer, David M.
    Epperson, Amanda L.
    Walker, Mark S.
    CLINICAL BREAST CANCER, 2012, 12 (02) : 87 - 93
  • [5] Phase II trial of nab-paclitaxel (nanoparticle albumin-bound paclitaxel (ABX)) plus capecitabine (XEL) in first-line treatment of metastatic breast cancer (MBC)
    Somer, B. G.
    Schwartzberg, L. S.
    Arena, F.
    Epperson, A.
    Fu, D.
    Fortner, B. V.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC)
    Conlin, A. K.
    Hudis, C. A.
    Bach, A.
    Moynahan, M.
    Lake, D.
    Forero-Torres, A.
    Wright, G.
    Hackney, M.
    Clawson, A.
    Seidman, A. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel With Carboplatin and Trastuzumab as First-line Therapy for Women With HER2-Overexpressing Metastatic Breast Cancer
    Conlin, Alison K.
    Seidman, Andrew D.
    Bach, Ariadne
    Lake, Diana
    Dickler, Maura
    D'Andrea, Gabriella
    Traina, Tiffany
    Danso, Michael
    Brufsky, Adam M.
    Saleh, Mansoor
    Clawson, Alicia
    Hudis, Clifford A.
    CLINICAL BREAST CANCER, 2010, 10 (04) : 281 - 287
  • [8] Randomized Phase II Trial of Weekly vs. q 2-Weekly vs. q 3-Weekly Nanoparticle Albumin-Bound Paclitaxel with Bevacizumab as First-Line Therapy for Metastatic Breast Cancer
    Seidman, A. D.
    Conlin, A. K.
    Bach, A.
    Forero-Torres, A.
    Wright, G.
    Hackney, M. H.
    Clawson, A.
    Schofield, D.
    Iglesias, J.
    Hudis, C. A.
    CANCER RESEARCH, 2011, 71
  • [9] A randomized, phase II trial of weekly paclitaxel versus weekly paclitaxel plus carboplatin for first-line metastatic breast cancer.
    Robert, N
    Loesch, D
    Lindquist, D
    Ratnam, S
    Hyman, W
    Whittaker, T
    Logie, K
    Kruger, S
    Pippen, J
    Liu, L
    Goldstein, L
    Asmar, L
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S129 - S129
  • [10] Final results of first-line weekly paclitaxel plus gemcitabine in metastatic breast cancer (MBC): an AERO phase II trial
    Mousseau, M.
    Serin, D.
    Goubely-Brewer, Y.
    Petit, T.
    Priou, F.
    Zelek, L.
    BULLETIN DU CANCER, 2007, 94 (06) : 569 - 570
12345